Aequus Pharmaceuticals Inc. Logo

Aequus Pharmaceuticals Inc.

AQSZF

(0.5)
Stock Price

0,00 USD

-283.8% ROA

50.78% ROE

-0.53x PER

Market Cap.

1.521.394,76 USD

-101.05% DER

0% Yield

-647.62% NPM

Aequus Pharmaceuticals Inc. Stock Analysis

Aequus Pharmaceuticals Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Aequus Pharmaceuticals Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's PBV ratio (2.52x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

2 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-153.16%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-41.62%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 DER

The company has a high debt to equity ratio (122%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Aequus Pharmaceuticals Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Aequus Pharmaceuticals Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Aequus Pharmaceuticals Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Aequus Pharmaceuticals Inc. Revenue
Year Revenue Growth
2013 0
2014 0 0%
2015 0 0%
2016 701.633 100%
2017 1.139.424 38.42%
2018 1.410.240 19.2%
2019 1.632.524 13.62%
2020 2.592.613 37.03%
2021 2.714.698 4.5%
2022 1.391.692 -95.06%
2022 1.379.772 -0.86%
2023 254.896 -441.31%
2024 645.652 60.52%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Aequus Pharmaceuticals Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2013 1.017.839
2014 1.041.424 2.26%
2015 2.144.488 51.44%
2016 1.127.780 -90.15%
2017 894.874 -26.03%
2018 526.935 -69.83%
2019 210.827 -149.94%
2020 54.608 -286.07%
2021 296.848 81.6%
2022 24.164 -1128.47%
2022 168.714 85.68%
2023 301.280 44%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Aequus Pharmaceuticals Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 408.909
2014 1.379.814 70.36%
2015 2.355.485 41.42%
2016 2.670.072 11.78%
2017 3.342.815 20.13%
2018 2.045.258 -63.44%
2019 1.782.110 -14.77%
2020 1.415.871 -25.87%
2021 1.704.947 16.96%
2022 1.261.132 -35.19%
2022 2.980.811 57.69%
2023 2.165.264 -37.67%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Aequus Pharmaceuticals Inc. EBITDA
Year EBITDA Growth
2013 -1.641.273
2014 -2.541.942 35.43%
2015 -5.012.117 49.28%
2016 -4.688.850 -6.89%
2017 -3.743.120 -25.27%
2018 -2.619.213 -42.91%
2019 -1.899.343 -37.9%
2020 -310.604 -511.5%
2021 -1.226.161 74.67%
2022 -1.935.700 36.66%
2022 -2.368.210 18.26%
2023 -2.682.130 11.7%
2024 -2.342.280 -14.51%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Aequus Pharmaceuticals Inc. Gross Profit
Year Gross Profit Growth
2013 0
2014 0 0%
2015 -86.778 100%
2016 701.633 112.37%
2017 1.139.424 38.42%
2018 1.410.240 19.2%
2019 1.632.524 13.62%
2020 2.592.613 37.03%
2021 2.688.919 3.58%
2022 1.293.216 -107.92%
2022 1.146.382 -12.81%
2023 5.499 -20747.1%
2024 167.076 96.71%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Aequus Pharmaceuticals Inc. Net Profit
Year Net Profit Growth
2013 -1.629.276
2014 -2.411.199 32.43%
2015 -5.011.405 51.89%
2016 -4.812.055 -4.14%
2017 -3.882.427 -23.94%
2018 -2.803.740 -38.47%
2019 -3.106.104 9.73%
2020 -1.045.360 -197.13%
2021 -1.809.592 42.23%
2022 -2.001.884 9.61%
2022 -3.210.044 37.64%
2023 -2.964.722 -8.27%
2024 -2.732.132 -8.51%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Aequus Pharmaceuticals Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Aequus Pharmaceuticals Inc. Free Cashflow
Year Free Cashflow Growth
2013 -883.549
2014 -1.364.877 35.27%
2015 -4.081.233 66.56%
2016 -4.944.358 17.46%
2017 -3.860.819 -28.07%
2018 -2.585.074 -49.35%
2019 -1.631.871 -58.41%
2020 -817.225 -99.68%
2021 -1.176.330 30.53%
2022 -539.019 -118.24%
2022 -1.952.579 72.39%
2023 -2.293.985 14.88%
2024 -706.104 -224.88%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Aequus Pharmaceuticals Inc. Operating Cashflow
Year Operating Cashflow Growth
2013 -876.058
2014 -1.364.877 35.81%
2015 -3.838.757 64.44%
2016 -4.465.418 14.03%
2017 -3.811.936 -17.14%
2018 -2.573.710 -48.11%
2019 -1.629.192 -57.97%
2020 -804.908 -102.41%
2021 -1.172.209 31.33%
2022 -539.019 -117.47%
2022 -1.952.579 72.39%
2023 -2.293.985 14.88%
2024 -706.104 -224.88%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Aequus Pharmaceuticals Inc. Capital Expenditure
Year Capital Expenditure Growth
2013 7.491
2014 0 0%
2015 242.476 100%
2016 478.940 49.37%
2017 48.883 -879.77%
2018 11.364 -330.16%
2019 2.679 -324.19%
2020 12.317 78.25%
2021 4.121 -198.88%
2022 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Aequus Pharmaceuticals Inc. Equity
Year Equity Growth
2013 280.595
2014 2.921.397 90.4%
2015 1.284.661 -127.41%
2016 1.265.684 -1.5%
2017 2.305.013 45.09%
2018 1.681.634 -37.07%
2019 -877.094 291.73%
2020 573.954 252.82%
2021 1.789.065 67.92%
2022 -363.789 591.79%
2022 -1.380.038 73.64%
2023 -4.293.844 67.86%
2024 -5.613.658 23.51%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Aequus Pharmaceuticals Inc. Assets
Year Assets Growth
2013 337.331
2014 3.665.904 90.8%
2015 2.429.738 -50.88%
2016 2.010.095 -20.88%
2017 2.671.849 24.77%
2018 1.996.531 -33.82%
2019 1.672.671 -19.36%
2020 3.134.684 46.64%
2021 4.348.115 27.91%
2022 2.672.748 -62.68%
2022 1.691.466 -58.01%
2023 1.086.223 -55.72%
2024 1.009.373 -7.61%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Aequus Pharmaceuticals Inc. Liabilities
Year Liabilities Growth
2013 56.736
2014 744.507 92.38%
2015 1.145.077 34.98%
2016 744.411 -53.82%
2017 366.836 -102.93%
2018 314.897 -16.49%
2019 2.549.765 87.65%
2020 2.560.730 0.43%
2021 2.559.050 -0.07%
2022 3.036.537 15.72%
2022 3.071.504 1.14%
2023 5.380.067 42.91%
2024 6.623.031 18.77%

Aequus Pharmaceuticals Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.02
Price to Earning Ratio
-0.53x
Price To Sales Ratio
5.47x
POCF Ratio
-0.55
PFCF Ratio
-0.55
Price to Book Ratio
-0.27
EV to Sales
27.58
EV Over EBITDA
-3.03
EV to Operating CashFlow
-2.76
EV to FreeCashFlow
-2.76
Earnings Yield
-1.88
FreeCashFlow Yield
-1.83
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.14
Graham NetNet
-0.05

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
0.97
ROE
0.62
Return On Assets
-3.12
Return On Capital Employed
0.43
Net Income per EBT
1
EBT Per Ebit
1.08
Ebit per Revenue
-6.02
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
4.7
Research & Developement to Revenue
0.27
Stock Based Compensation to Revenue
0.1
Gross Profit Margin
0.37
Operating Profit Margin
-6.02
Pretax Profit Margin
-6.48
Net Profit Margin
-6.48

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.02
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-45.14
Return on Tangible Assets
-2.84
Days Sales Outstanding
157.29
Days Payables Outstanding
479.67
Days of Inventory on Hand
223.06
Receivables Turnover
2.32
Payables Turnover
0.76
Inventory Turnover
1.64
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,04
Tangible Book Value per Share
-0.04
Shareholders Equity per Share
-0.04
Interest Debt per Share
0.04
Debt to Equity
-1.01
Debt to Assets
5.62
Net Debt to EBITDA
-2.43
Current Ratio
0.07
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-5091056
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
119613
Debt to Market Cap
3.73

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Aequus Pharmaceuticals Inc. Dividends
Year Dividends Growth

Aequus Pharmaceuticals Inc. Profile

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

CEO
Mr. Douglas Glen Janzen
Employee
12
Address
200 Granville Street
Vancouver, V6C 1S4

Aequus Pharmaceuticals Inc. Executives & BODs

Aequus Pharmaceuticals Inc. Executives & BODs
# Name Age
1 Mr. Douglas Glen Janzen
Chairman, Chief Executive Officer & President
70

Aequus Pharmaceuticals Inc. Competitors